SHUTTLE PHARMACEUTICALS HOLD (SHPH) Fundamental Analysis & Valuation

NASDAQ:SHPH • US8256934014

Current stock price

1.02 USD
-0.01 (-0.97%)
At close:
1.01 USD
-0.01 (-0.98%)
Pre-Market:

This SHPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SHPH Profitability Analysis

1.1 Basic Checks

  • In the past year SHPH has reported negative net income.
  • SHPH had a negative operating cash flow in the past year.
  • In the past 5 years SHPH always reported negative net income.
  • SHPH had a negative operating cash flow in each of the past 5 years.
SHPH Yearly Net Income VS EBIT VS OCF VS FCFSHPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • The Return On Assets of SHPH (-302.20%) is worse than 92.44% of its industry peers.
  • SHPH has a Return On Equity of -767.95%. This is in the lower half of the industry: SHPH underperforms 79.84% of its industry peers.
Industry RankSector Rank
ROA -302.2%
ROE -767.95%
ROIC N/A
ROA(3y)-170.32%
ROA(5y)-174.67%
ROE(3y)-496.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SHPH Yearly ROA, ROE, ROICSHPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SHPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SHPH Yearly Profit, Operating, Gross MarginsSHPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. SHPH Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, SHPH has more shares outstanding
  • The debt/assets ratio for SHPH is higher compared to a year ago.
SHPH Yearly Shares OutstandingSHPH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50K 100K 150K
SHPH Yearly Total Debt VS Total AssetsSHPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

  • SHPH has an Altman-Z score of -25.39. This is a bad value and indicates that SHPH is not financially healthy and even has some risk of bankruptcy.
  • SHPH has a Altman-Z score of -25.39. This is amonst the worse of the industry: SHPH underperforms 86.63% of its industry peers.
  • SHPH has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
  • SHPH has a worse Debt to Equity ratio (0.30) than 68.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z -25.39
ROIC/WACCN/A
WACCN/A
SHPH Yearly LT Debt VS Equity VS FCFSHPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

  • SHPH has a Current Ratio of 1.66. This is a normal value and indicates that SHPH is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.66, SHPH is doing worse than 81.01% of the companies in the same industry.
  • SHPH has a Quick Ratio of 1.66. This is a normal value and indicates that SHPH is financially healthy and should not expect problems in meeting its short term obligations.
  • SHPH has a Quick ratio of 1.66. This is in the lower half of the industry: SHPH underperforms 79.46% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
SHPH Yearly Current Assets VS Current LiabilitesSHPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SHPH Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 9.87% over the past year.
EPS 1Y (TTM)9.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. SHPH Valuation Analysis

4.1 Price/Earnings Ratio

  • SHPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SHPH Price Earnings VS Forward Price EarningsSHPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SHPH Per share dataSHPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SHPH Dividend Analysis

5.1 Amount

  • No dividends for SHPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SHPH Fundamentals: All Metrics, Ratios and Statistics

SHUTTLE PHARMACEUTICALS HOLD

NASDAQ:SHPH (4/17/2026, 8:00:02 PM)

Premarket: 1.01 -0.01 (-0.98%)

1.02

-0.01 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners2.09%
Inst Owner Change0%
Ins Owners0.81%
Ins Owner Change0%
Market Cap5.70M
Revenue(TTM)N/A
Net Income(TTM)-10.71M
AnalystsN/A
Price TargetN/A
Short Float %2.09%
Short Ratio0.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.09
P/tB 4.09
EV/EBITDA N/A
EPS(TTM)-25.87
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2
FCFYN/A
OCF(TTM)-2
OCFYN/A
SpS0
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -302.2%
ROE -767.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-170.32%
ROA(5y)-174.67%
ROE(3y)-496.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -25.39
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.35%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-114.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-115.4%
OCF growth 3YN/A
OCF growth 5YN/A

SHUTTLE PHARMACEUTICALS HOLD / SHPH Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SHUTTLE PHARMACEUTICALS HOLD (SHPH) stock?

ChartMill assigns a fundamental rating of 0 / 10 to SHPH.


What is the valuation status for SHPH stock?

ChartMill assigns a valuation rating of 0 / 10 to SHUTTLE PHARMACEUTICALS HOLD (SHPH). This can be considered as Overvalued.


What is the profitability of SHPH stock?

SHUTTLE PHARMACEUTICALS HOLD (SHPH) has a profitability rating of 0 / 10.